Cargando…

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial

BACKGROUND: Class II histone deacetylase (HDAC) inhibitors induce hypoxia-inducible factor-1 and -2α degradation and have antitumour effects in combination with vascular endothelial growth factor (VEGF) inhibitors. In this study, we tested the safety and efficacy of the HDAC inhibitor vorinostat and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pili, Roberto, Liu, Glenn, Chintala, Sreenivasulu, Verheul, Hendrick, Rehman, Shabnam, Attwood, Kristopher, Lodge, Martin A, Wahl, Richard, Martin, James I, Miles, Kiersten Marie, Paesante, Silvia, Adelaiye, Remi, Godoy, Alejandro, King, Serina, Zwiebel, James, Carducci, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379145/ https://www.ncbi.nlm.nih.gov/pubmed/28222071 http://dx.doi.org/10.1038/bjc.2017.33

Ejemplares similares

YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage
por: Ciamporcero, Eric, et al.
Publicado: (2015)

Genomic profiling of collecting duct renal carcinoma
por: Chintala, Sreenivasulu, et al.
Publicado: (2016)

Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
por: Pili, R, et al.
Publicado: (2012)

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells
por: Eto, Shotaro, et al.
Publicado: (2019)

Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts
por: Miles, Kiersten Marie, et al.
Publicado: (2014)

Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
por: Hrzenjak, Andelko, et al.
Publicado: (2010)

Effect of histone deacetylase inhibitor (vorinostat) on new-onset diabetes induced by tacrolimus
por: Bakhdar, Fatmah A., et al.
Publicado: (2022)

Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
por: Saelen, Marie Grøn, et al.
Publicado: (2012)

Concurrent HDAC and mTORC1 Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated with Alterations in MicroRNA Expression
por: Ellis, Leigh, et al.
Publicado: (2011)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells
por: Phillip, Cornel J, et al.
Publicado: (2012)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma
por: Ramakrishnan, Swathi, et al.
Publicado: (2016)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

The Mechanism of Action of the Histone Deacetylase Inhibitor Vorinostat Involves Interaction with the Insulin-Like Growth Factor Signaling Pathway
por: Sarfstein, Rive, et al.
Publicado: (2011)

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
por: Munster, P N, et al.
Publicado: (2009)

The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
por: Hutt, Darren M., et al.
Publicado: (2014)

Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis
por: Laengle, Johannes, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest
por: Yang, Yang, et al.
Publicado: (2021)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat
por: Maxwell, Jill W., et al.
Publicado: (2020)

Brief Report: Case Comparison of Therapy With the Histone Deacetylase Inhibitor Vorinostat in a Neonatal Calf Model of Pulmonary Hypertension
por: Applegate, Tanya J., et al.
Publicado: (2021)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
por: LaBonte, Melissa J, et al.
Publicado: (2009)

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
por: Mettananda, Sachith, et al.
Publicado: (2019)

Crafting Carbazole-Based Vorinostat and Tubastatin-A-like Histone Deacetylase (HDAC) Inhibitors with Potent in Vitro and in Vivo Neuroactive Functions
por: Reddy, R. Gajendra, et al.
Publicado: (2019)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
por: Munster, P N, et al.
Publicado: (2011)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
por: Bernhart, Eva, et al.
Publicado: (2017)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
por: Chintala, Sreenivasulu, et al.
Publicado: (2012)

Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer
por: Fontana, Luigi, et al.
Publicado: (2013)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_bu51lntq9puootmu1cvje4vdrn